TriangleSorafenib, Bevacizumab and… (NCT05468359)
Sorafenib, Bevacizumab and Atezolizumab trial for Refractory Pediatric Solid Tumors (NCT05468359). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for children, teens and young adults under 30 whose solid tumors have relapsed or not responded to treatment, including fibrolamellar carcinoma.
The idea: combine four drugs. Atezolizumab and bevacizumab are given by vein every three weeks, with daily low-dose cyclophosphamide and sorafenib by mouth.
This phase 1 and 2 study first looks at safety and the recommended doses, then at response. It plans 64 participants. At St. Jude Children's Research Hospital in Memphis, Jessica Gartrell leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.